Price alert —
Sign in to get a one-time email the moment RHHBY crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · RHHBY
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
No quarterly financials available.
Compare RHHBY vs peers
Line RHHBY up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
RHHBY
RHHBY
$51.60
+0.29%
META
META
$646.01
-2.79%
AVGO
AVGO
$370.83
-0.97%
Earnings replay · last 5 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2010-07-22 | 2.65 | 3.15 | -15.8% | — |
| 2010-05-04 | 2.51 | — | — | — |
| 2006-07-20 | 0.44 | 0.44 | — | — |
| 2006-02-01 | 0.25 | 0.30 | -17.4% | — |
| 2005-07-20 | 0.33 | 0.34 | -4.1% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| RHHBY ★ | $332B | 20.7 | 16.1 | 5.2 | 14.6 | 7.9 | 74.5% | -0.4% | 171.3% | 3.32% |
| LLY | $1,051B | 41.5 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 31.8 | 19.2 | 0.9 | 20.2 | 4.0 | 18.8% | 2.0% | 0.7% | 4.57% |
| JNJ | $609B | 29.0 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.8 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 0.08%
| Holder | Shares | % out |
|---|---|---|
| Aristotle Capital Management, LLC | 2,063,885 | 0.04% |
| Saratoga Research & Investment Manag | 1,291,630 | 0.02% |
| Boston Common Asset Management, LLC | 322,354 | 0.01% |
| Old National Bancorp/IN/ | 287,612 | 0.01% |
| Hantz Financial Services, Inc. | 215,187 | — |
| Altrius Capital Management Inc | 176,959 | — |
| S & CO., INC. | 140,551 | — |
| Rhumbline Advisers | 98,944 | — |
| AR Asset Management, Inc. | 107,700 | — |
| Huntington National Bank | 122,990 | — |
Insider activity · 90d
No insider trades for RHHBY in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
No CIK found for RHHBY.
About RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
Options picks · RHHBY
ITM + OTM ideas from the latest scanLoading…
Congress trades · RHHBY
STOCK Act disclosuresLoading…
SEC filings & insiders · RHHBY
EDGAR · liveLoading…
Holders · RHHBY
Institutions & insider activityLoading…